Phase II study of the predictive value of the expression of tumoral MGMT [methylguanine methyltransferase] with respect to the therapeutic response of fotemustine in patients with metastatic malignant melanoma

Trial Profile

Phase II study of the predictive value of the expression of tumoral MGMT [methylguanine methyltransferase] with respect to the therapeutic response of fotemustine in patients with metastatic malignant melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 13 May 2011

At a glance

  • Drugs Fotemustine (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 May 2011 Actual end date (May 2011) added as reported by ClinicalTrials.gov.
    • 13 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 May 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top